Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

10 Years CECOG

10 Years CECOG CECOG News memo (2009) Vol. 2: 5 DOI 10.1007/s12254-008-0079-1 Printed in Austria © Springer-Verlag 2009 Since its foundation, CECOG has evolved into a true Molecular targeted therapies in breast cancer international cooperative study group being impressively (moderator: Z. Kahan, Hungary) active in Central- and South-Eastern Europe and other European and non-European countries, comprising more – Bevacizumab in Breast Cancer: Th e CECOG concept than 150 academic centres in 23 countries. During the past (T. Pienkowski, Poland); years, CECOG terminated 15 clinical trials in which almost – Th e role of anthracycline-based treatment in breast cancer: 2,700 patients had been enrolled. Th e CECOG experience (R. Anghel, Romania); Besides conducting clinical trials, CECOG also acts as an – Her-2/neu positive Breast Cancer: Trastuzumab beyond educational task group by organising Consensus Development Progression: Th e Viennese and the CECOG experience Conferences, uniting opinions of high-ranking specialists in (G. Steger, Austria); each fi eld from Central- and South-Eastern Europe as well as other parts of the world to establish internationally accepted consensus on minimal standards of diagnosis and medical treatment of non-small-cell lung cancer, metastatic breast The next step forward in NSCLC treatment cancer and metastatic colon cancer. With this approach, we http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

10 Years CECOG

memo - Magazine of European Medical Oncology , Volume 2 (1) – Jan 1, 2008
Download PDF
1 page

10 Years CECOG

Abstract

CECOG News memo (2009) Vol. 2: 5 DOI 10.1007/s12254-008-0079-1 Printed in Austria © Springer-Verlag 2009 Since its foundation, CECOG has evolved into a true Molecular targeted therapies in breast cancer international cooperative study group being impressively (moderator: Z. Kahan, Hungary) active in Central- and South-Eastern Europe and other European and non-European countries, comprising more – Bevacizumab in Breast Cancer: Th e CECOG concept than 150 academic centres in 23...
Loading next page...
 
/lp/springer-journals/10-years-cecog-aXlhFzs20C
Publisher
Springer Journals
Copyright
Copyright © 2009 by Springer-Verlag
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-008-0079-1
Publisher site
See Article on Publisher Site

Abstract

CECOG News memo (2009) Vol. 2: 5 DOI 10.1007/s12254-008-0079-1 Printed in Austria © Springer-Verlag 2009 Since its foundation, CECOG has evolved into a true Molecular targeted therapies in breast cancer international cooperative study group being impressively (moderator: Z. Kahan, Hungary) active in Central- and South-Eastern Europe and other European and non-European countries, comprising more – Bevacizumab in Breast Cancer: Th e CECOG concept than 150 academic centres in 23 countries. During the past (T. Pienkowski, Poland); years, CECOG terminated 15 clinical trials in which almost – Th e role of anthracycline-based treatment in breast cancer: 2,700 patients had been enrolled. Th e CECOG experience (R. Anghel, Romania); Besides conducting clinical trials, CECOG also acts as an – Her-2/neu positive Breast Cancer: Trastuzumab beyond educational task group by organising Consensus Development Progression: Th e Viennese and the CECOG experience Conferences, uniting opinions of high-ranking specialists in (G. Steger, Austria); each fi eld from Central- and South-Eastern Europe as well as other parts of the world to establish internationally accepted consensus on minimal standards of diagnosis and medical treatment of non-small-cell lung cancer, metastatic breast The next step forward in NSCLC treatment cancer and metastatic colon cancer. With this approach, we

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Jan 1, 2008

There are no references for this article.